COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL-[1,2,4] TRIAZOLO [4,3-A] QUINOXALINE COMPOUNDS AND PED 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS
MEGENS, ANTONIUS ADRIANUS HENDRIKUS PETRUS,LANGLOIS, XAVIER JEAN MICHEL,VANHOOF, GRETA CONSTANTIA PETER,ANDRS-GIL, JOS IGNACIO,DE ANGELIS MERI,BUIJNSTERS, PETER JACOBUS JOHANNES ANTONIUS,TRABANCO-SURE
申请号：
HK15106810.8
公开号：
HK1206250A
申请日:
2015.07.17
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE 10). In particular, the invention relates to combinations of 1-aryl-4- methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051342 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1- aryl-4-methyl- [1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases.La présente invention concerne des combinaisons dinhibiteurs de la phosphodiestérase 2 (PDE 2) et dinhibiteurs de la phosphodiestérase 10 (PDE 10). La présente invention concerne en particulier des combinaisons de dérivés de la 1-aryl-4-méthyl-[1, 2, 4] triazolo [4, 3-a]-quinoxaline, que lon a constaté comme inhibant la phosphodiestérase 2 (PDE 2), et dinhibiteurs de la phosphodiestérase 10 (PDE 10). Des inhibiteurs spécifiques de la PDE 10 sont choisis dans le groupe comprenant la MP-10, la PQ-10, la TP-10, la papavérine, et les composés que décrivent les documents WO 2011/051342 et WO 2011/110545. Linvention concerne également des compositions pharmaceutiques comprenant ces combinaisons, des traitements de préparation de ces compositions, lutilisation din
